Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -6% Improvement Relative Risk c19hcq.org Rodriguez-Nava et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 313 patients in the USA No significant difference in mortality Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes Favors HCQ Favors control
Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Rodriguez-Nava et al., Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community.., Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support, showing unadjusted RR 1.06, p = 0.77. Confounding by indication likely. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; excessive unadjusted differences between groups; unadjusted results with no group details.
risk of death, 6.3% higher, RR 1.06, p = 0.77, treatment 22 of 65 (33.8%), control 79 of 248 (31.9%), unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rodriguez-Nava et al., 5 Nov 2020, retrospective, USA, peer-reviewed, median age 68.0, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: ORIGINAL ARTICLE Clinical Characteristics and Risk Factors for Death of Hospitalized Patients With COVID19 in a Community Hospital: A Retrospective Cohort Study Guillermo Rodriguez-Nava, MD; Maria Adriana Yanez-Bello, MD; Daniela Patricia Trelles-Garcia, MD; Chul Won Chung, MD; Sana Chaudry, MD; Aimen S. Khan, MD; Harvey J. Friedman, MD, FACP; and David W. Hines, MD Abstract Objective: To describe the clinical characteristics, outcomes, and risk factors for death of patients with coronavirus disease 2019 (COVID-19) in a community hospital setting. Patients and Methods: This single-center retrospective cohort study included 313 adult patients with laboratory-confirmed COVID-19 admitted to a community hospital in Cook County, Illinois, from March 1, 2020, to May 25, 2020. Demographics, medical history, underlying comorbidities, symptoms, signs, laboratory findings, imaging studies, management, and progression to discharge or death data were collected and analyzed. Results: Of 313 patients, the median age was 68 years (interquartile range, 59.0-78.5 years; range, 19-98 years), 182 (58.1%) were male, 119 (38%) were white, and 194 (62%) were admitted from a long-term care facility (LTCF). As of May 25, 2020, there were 212 (67.7%) survivors identified, whereas 101 (32.3%) nonsurvivors were identified. Multivariable Cox regression analysis showed increasing hazards of inpatient death associated with older age (hazard ratio [HR] 1.02; 95% CI, 1.01-1.04), LTCF residence (HR, 3.23; 95% CI, 1.68-6.20), and quick Sequential Organ Failure Assessment scores (HR, 2.59; 95% CI, 1.78-3.76). Conclusion: In this single-center retrospective cohort study of 313 adult patients hospitalized with COVID-19 illness in a community hospital in Cook County, Illinois, older patients, LTCF residents, and patients with high quick Sequential Organ Failure Assessment scores were found to have worse clinical outcomes and increased risk of death. ª 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc Inn Qual Out 2021;5(1):1-10 O n December 31, 2019, the World Health Organization received a report of a cluster of cases of pneumonia of unknown etiology detected in Wuhan City, Hubei Province of China.1 The pathogen was identified as a novel enveloped RNA betacoronavirus, different from both Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus, later designated severe acute respiratory syndrome coronavirus 2.2 The disease that it causes was later named coronavirus disease 2019 (COVID-19).3 This new disease rapidly spread globally, prompting the World Health Organization to declare it a pandemic on March 11, 2020. The United States has been, to date, the country with the highest incidence of the disease. As of June 2, 2020, there had been a total of 1,802,470 cases reported in the United States; in Cook County, Illinois, there had been 78,495 confirmed cases.4,5 After the emergence of this novel pathogen, several cohort and case series studies have described COVID-19 in populations overseas and large US academic centers.6-17 Ecologic studies have found significant differences within the US territory regarding mortality patterns as a function of geographic location and population composition.18 Also, detailed data on demographic characteristics, comorbidities, risk factors, and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit